Advanced search
Publication Cover
Expert Review of Neurotherapeutics Volume 13, 2013 - Issue 6
Submit an article Journal homepage
354
Views
8
CrossRef citations to date
0
Altmetric
Drug Profile

Fingolimod for the treatment of relapsing multiple sclerosis

Barry A Singer The MS Center for Innovations in Care, Missouri Baptist Medical Center, St Louis, MO 63131, USA. [email protected]
Pages 589-602 | Published online: 09 Jan 2014

References

  • Bejaoui K, Rolak LA. What is the risk of permanent disability from a multiple sclerosis relapse? Neurology 74(11), 900–902 (2010).
  • Lublin FD, Baier M, Cutter G. Effect of relapses on development of residual deficit in multiple sclerosis. Neurology 61(11), 1528–1532 (2003).
  • Confavreux C, Vukusic S. Natural history of multiple sclerosis: a unifying concept. Brain 129(Pt 3), 606–616 (2006).
  • Giovannoni G, Southam E, Waubant E. Systematic review of disease-modifying therapies to assess unmet needs in multiple sclerosis: tolerability and adherence. Mult. Scler. 18(7), 932–946 (2012).
  • Singer B, Lucas S, Kresa-Reahl K, Ross AP, Blake P. Review: optimizing adherence to multiple sclerosis therapies. Int. J. MS Care 10(4), 113–126 (2008).
  • Novantrone® (Mitoxantrone), full prescribing information. EMD Serono, Inc., MA, USA (2012).
  • Tysabri® (Natalizumab), full prescribing information. Biogen-Idec, Inc., MA, USA (2012).
  • Summary Basis of Decision GILENYA. Health Canada (2011).
  • Gilenya™ (fingolimod), full prescribing information. Novartis Pharmaceuticals Corporation, NJ, USA (2012).
  • Gilenya™ (fingolimod), Summary of product characteristics. Novartis Europharm Limited, UK, (2011).
  • O’Connor P, Wolinsky JS, Confavreux C et al.; TEMSO Trial Group. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N. Engl. J. Med. 365(14), 1293–1303 (2011).
  • Kappos L, Comi G, Confavreux C et al. The efficacy and safety of teriflunomide in patients with relapsing MS: results from TOWER, a Phase III placebo-controlled study. Presented at: 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Lyon, France, 10–13 October 2012.
  • Fox RJ, Miller DH, Phillips JT et al.; CONFIRM Study Investigators. Placebo-controlled Phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N. Engl. J. Med. 367(12), 1087–1097 (2012).
  • Gold R, Kappos L, Arnold DL et al.; DEFINE Study Investigators. Placebo-controlled Phase 3 study of oral BG-12 for relapsing multiple sclerosis. N. Engl. J. Med. 367(12), 1098–1107 (2012).
  • Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu. Rev. Immunol. 22, 745–763 (2004).
  • Mehling M, Lindberg R, Raulf F et al. Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis. Neurology 75(5), 403–410 (2010).
  • Tzartos JS, Friese MA, Craner MJ et al. Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am. J. Pathol. 172(1), 146–155 (2008).
  • Obermeier B, Lovato L, Mentele R et al. Related B cell clones that populate the CSF and CNS of patients with multiple sclerosis produce CSF immunoglobulin. J. Neuroimmunol. 233(1–2), 245–248 (2011).
  • Disanto G, Morahan JM, Barnett MH, Giovannoni G, Ramagopalan SV. The evidence for a role of B cells in multiple sclerosis. Neurology 78(11), 823–832 (2012).
  • Owens GP, Ritchie AM, Burgoon MP, Williamson RA, Corboy JR, Gilden DH. Single-cell repertoire analysis demonstrates that clonal expansion is a prominent feature of the B cell response in multiple sclerosis cerebrospinal fluid. J. Immunol. 171(5), 2725–2733 (2003).
  • Hauser SL, Waubant E, Arnold DL et al.; HERMES Trial Group. B-cell depletion with rituximab in relapsing–remitting multiple sclerosis. N. Engl. J. Med. 358(7), 676–688 (2008).
  • Kappos L, Li D, Calabresi PA et al. Ocrelizumab in relapsing–remitting multiple sclerosis: a Phase 2, randomised, placebo-controlled, multicentre trial. Lancet 378(9805), 1779–1787 (2011).
  • Naismith RT, Piccio L, Lyons JA et al. Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week Phase II trial. Neurology 74(23), 1860–1867 (2010).
  • Sofroniew MV, Vinters HV. Astrocytes: biology and pathology. Acta Neuropathol. 119(1), 7–35 (2010).
  • Gao Z, Tsirka SE. Animal models of MS reveal multiple roles of microglia in disease pathogenesis. Neurol. Res. Int. 2011, 383087 (2011).
  • Noda H, Takeuchi H, Mizuno T, Suzumura A. Fingolimod phosphate promotes the neuroprotective effects of microglia. J. Neuroimmunol. 256(1–2), 13–18 (2013).
  • Jana A, Pahan K. Sphingolipids in multiple sclerosis. Neuromolecular Med. 12(4), 351–361 (2010).
  • Brinkmann V. FTY720 (fingolimod) in multiple sclerosis: therapeutic effects in the immune and the central nervous system. Br. J. Pharmacol. 158(5), 1173–1182 (2009).
  • Kharel Y, Lee S, Snyder AH et al. Sphingosine kinase 2 is required for modulation of lymphocyte traffic by FTY720. J. Biol. Chem. 280(44), 36865–36872 (2005).
  • Zemann B, Kinzel B, Müller M et al. Sphingosine kinase type 2 is essential for lymphopenia induced by the immunomodulatory drug FTY720. Blood 107(4), 1454–1458 (2006).
  • Brinkmann V, Davis MD, Heise CE et al. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J. Biol. Chem. 277(24), 21453–21457 (2002).
  • Mandala S, Hajdu R, Bergstrom J et al. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 296(5566), 346–349 (2002).
  • Gräler MH, Goetzl EJ. The immunosuppressant FTY720 down-regulates sphingosine 1-phosphate G-protein-coupled receptors. FASEB J. 18(3), 551–553 (2004).
  • Matloubian M, Lo CG, Cinamon G et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 427(6972), 355–360 (2004).
  • Oo ML, Thangada S, Wu MT et al. Immunosuppressive and anti-angiogenic sphingosine 1-phosphate receptor-1 agonists induce ubiquitinylation and proteasomal degradation of the receptor. J. Biol. Chem. 282(12), 9082–9089 (2007).
  • Chae SS, Proia RL, Hla T. Constitutive expression of the S1P1 receptor in adult tissues. Prostaglandins Other Lipid Mediat. 73(1–2), 141–150 (2004).
  • Jaillard C, Harrison S, Stankoff B et al. Edg8/S1P5: an oligodendroglial receptor with dual function on process retraction and cell survival. J. Neurosci. 25(6), 1459–1469 (2005).
  • Mehling M, Brinkmann V, Antel J et al. FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis. Neurology 71(16), 1261–1267 (2008).
  • Chiba K, Yanagawa Y, Masubuchi Y et al. FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. I. FTY720 selectively decreases the number of circulating mature lymphocytes by acceleration of lymphocyte homing. J. Immunol. 160(10), 5037–5044 (1998).
  • Foster CA, Howard LM, Schweitzer A et al. Brain penetration of the oral immunomodulatory drug FTY720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: consequences for mode of action in multiple sclerosis. J. Pharmacol. Exp. Ther. 323(2), 469–475 (2007).
  • Meno-Tetang GM, Li H, Mis S et al. Physiologically based pharmacokinetic modeling of FTY720 (2-amino-2[2-(-4-octylphenyl)ethyl]propane-1,3-diol hydrochloride) in rats after oral and intravenous doses. Drug Metab. Dispos. 34(9), 1480–1487 (2006).
  • Tamagnan G, Tavares A, Barret O et al. Brain distribution of BZM055, an analog of fingolimod (FTY720), in human. Presented at: 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Lyon, France, 10–13 October 2012.
  • Choi JW, Gardell SE, Herr DR et al. FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation. Proc. Natl Acad. Sci. USA 108(2), 751–756 (2011).
  • Miron VE, Ludwin SK, Darlington PJ et al. Fingolimod (FTY720) enhances remyelination following demyelination of organotypic cerebellar slices. Am. J. Pathol. 176(6), 2682–2694 (2010).
  • Hu Y, Lee X, Ji B et al. Sphingosine 1-phosphate receptor modulator fingolimod (FTY720) does not promote remyelination in vivo. Mol. Cell. Neurosci. 48(1), 72–81 (2011).
  • Deogracias R, Yazdani M, Dekkers MP et al. Fingolimod, a sphingosine-1 phosphate receptor modulator, increases BDNF levels and improves symptoms of a mouse model of Rett syndrome. Proc. Natl Acad. Sci. USA 109(35), 14230–14235 (2012).
  • Chun J, Cohen JA. Fingolimod mechanism of action in multiple sclerosis. Presented at: American Neurological Association 136th Annual Meeting. San Diego, CA, USA, 25–27 September 2011.
  • Walzer T, Chiossone L, Chaix J et al. Natural killer cell trafficking in vivo requires a dedicated sphingosine 1-phosphate receptor. Nat. Immunol. 8(12), 1337–1344 (2007).
  • van Doorn R, Nijland PG, Dekker N et al. Fingolimod attenuates ceramide-induced blood-brain barrier dysfunction in multiple sclerosis by targeting reactive astrocytes. Acta Neuropathol. 124(3), 397–410 (2012).
  • Kulakowska A, Zendzian-Piotrowska M, Baranowski M et al. Intrathecal increase of sphingosine 1-phosphate at early stage multiple sclerosis. Neurosci. Lett. 477(3), 149–152 (2010).
  • Van Doorn R, Van Horssen J, Verzijl D et al. Sphingosine 1-phosphate receptor 1 and 3 are upregulated in multiple sclerosis lesions. Glia 58(12), 1465–1476 (2010).
  • Kovarik JM, Schmouder R, Barilla D, Riviere GJ, Wang Y, Hunt T. Multiple-dose FTY720: tolerability, pharmacokinetics, and lymphocyte responses in healthy subjects. J. Clin. Pharmacol. 44(5), 532–537 (2004).
  • Cohen JA, Barkhof F, Comi G et al.; TRANSFORMS Study Group. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N. Engl. J. Med. 362(5), 402–415 (2010).
  • Kappos L, Radue EW, O’Connor P et al.; FREEDOMS Study Group. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N. Engl. J. Med. 362(5), 387–401 (2010).
  • Mehling M, Hilbert P, Fritz S et al. Antigen-specific adaptive immune responses in fingolimod-treated multiple sclerosis patients. Ann. Neurol. 69(2), 408–413 (2011).
  • Pinschewer DD, Ochsenbein AF, Odermatt B, Brinkmann V, Hengartner H, Zinkernagel RM. FTY720 immunosuppression impairs effector T cell peripheral homing without affecting induction, expansion, and memory. J. Immunol. 164(11), 5761–5770 (2000).
  • Kappos L, Antel J, Comi G et al.; FTY720 D2201 Study Group. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N. Engl. J. Med. 355(11), 1124–1140 (2006).
  • Radue EW, O’Connor P, Polman CH et al.; FTY720 Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) Study Group. Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis. Arch. Neurol. 69(10), 1259–1269 (2012).
  • Calabresi PA. Efficacy and safety of fingolimod in patients with relapsing–remitting multiple sclerosis (RRMS): results from an additional 24-month double-blind, placebo-controlled study (FREEDOMS II Study). Presented at: American Academy of Neurology 64th Annual Meeting. New Orleans, LA, USA, 25 April 2012.
  • Chin PS, Calabresi P, Zhang Y, Von Rosenstiel P, Kappos L. Early effect of fingolimod on clinical and MRI related outcomes in relapsing multiple sclerosis. Presented at: 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Lyon, France, 10–13 October 2012.
  • Comi G, O’Connor P, Montalban X et al.; FTY720D2201 Study Group. Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results. Mult. Scler. 16(2), 197–207 (2010).
  • Kappos L, Radue EW, O’Connor P et al. Phase 3 FREEDOMS study extension: fingolimod (FTY720) efficacy in patients with relapsing–remitting multiple sclerosis receiving continuous or placebo–fingolimod switched therapy for up to 4 years. Presented at: 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Lyon, France, 10–13 October 2012.
  • Khatri B, Barkhof F, Comi G et al.; TRANSFORMS Study Group. Comparison of fingolimod with interferon β-1a in relapsing–remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. Lancet Neurol. 10(6), 520–529 (2011).
  • Cohen JA, O’Connor P, Caliolio T et al. Long-term safety of fingolimod in relapsing multiple sclerosis: update to integrated analyses of Phase 2 and 3 studies and extension phases. Presented at: 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Lyon, France, 10–13 October 2012.
  • O’Connor P, Polman C, Hohlfeld R et al. Phase 3 FREEDOMS study extension: long-term safety of fingolimod (FTY720) in relapsing–remitting multiple sclerosis. Presented at: 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Lyon, France, 10–13 October 2012.
  • Means CK, Brown JH. Sphingosine-1-phosphate receptor signalling in the heart. Cardiovasc. Res. 82(2), 193–200 (2009).
  • Koyrakh L, Roman MI, Brinkmann V, Wickman K. The heart rate decrease caused by acute FTY720 administration is mediated by the G protein-gated potassium channel I. Am. J. Transplant. 5(3), 529–536 (2005).
  • Brossard P, Halabi A, Derendorf H, Dingemanse J. Ascending single-dose study with ponesimod, a selective S1P1 receptor agonist: safety, pharmacokinetics, pharmacodynamics, and modeling. Presented at: American Society for Clinical Pharmacology and Therapeutics Annual Meeting. National Harbor, MD, USA, 12–17 March 2012.
  • Gergely P, Nuesslein-Hildesheim B, Guerini D et al. The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate. Br. J. Pharmacol. 167(5), 1035–1047 (2012).
  • Zipp F, Vollmer TL, Selmaj KW, Bar-Or A, Group Obot DS. Efficacy and safety of the S1P receptor agonist ONO-4641 in patients with relapsing–remitting multiple sclerosis: results of a 26-week, double-blind, placebo-controlled, Phase II trial (DreaMS). Presented at: 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Lyon, France, 10–13 October 2012.
  • DiMarco JP, O’Connor P, Cohen JA et al. Fingolimod treatment initiation experience: cardiac and Holter electrocardiogram findings from three Phase 3 studies. Presented at: 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Lyon, France, 10–13 October 2012.
  • Lindsey JW, Haden-Pinneri K, Memon NB, Buja LM. Sudden unexpected death on fingolimod. Mult. Scler. 18(10), 1507–1508 (2012).
  • Espinosa PS, Berger JR. Delayed fingolimod-associated asystole. Mult. Scler. 17(11), 1387–1389 (2011).
  • Francis G, Kappos L, O’Connor P et al. Lymphocytes and fingolimod – temporal pattern and relationship with infections. Presented at: 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Gothenburg, Sweden, 13–16 October 2010.
  • Francis G, Kappos L, O’Connor P et al. Lymphocytes and fingolimod: temporal pattern and relationship with infections. Presented at: American Academy of Neurology Annual Meeting. Honolulu, HI, USA, 9–16 April 2011.
  • Geissbuhler Y, Butzkueven H, Hernandez-Diaz S et al. Pregnancy outcomes from fingolimod clinical trials and post-marketing experience and the need for a multinational Gilenya™ (fingolimod) Pregnancy Exposure Registry in Multiple Sclerosis. Presented at: 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Lyon, France, 12 October 2012.
  • Leypoldt F, Münchau A, Moeller F, Bester M, Gerloff C, Heesen C. Hemorrhaging focal encephalitis under fingolimod (FTY720) treatment: a case report. Neurology 72(11), 1022–1024 (2009).
  • Visser F, Wattjes MP, Pouwels PJ, Linssen WH, van Oosten BW. Tumefactive multiple sclerosis lesions under fingolimod treatment. Neurology 79(19), 2000–2003 (2012).
  • Castrop F, Kowarik MC, Albrecht H et al. Severe multiple sclerosis relapse under fingolimod therapy: incident or coincidence? Neurology 78(12), 928–930 (2012).
  • Havla JB, Pellkofer HL, Meinl I, Gerdes LA, Hohlfeld R, Kümpfel T. Rebound of disease activity after withdrawal of fingolimod (FTY720) treatment. Arch. Neurol. 69(2), 262–264 (2012).
  • Schwarz A, Korporal M, Hosch W, Max R, Wildemann B. Critical vasospasm during fingolimod (FTY720) treatment in a patient with multiple sclerosis. Neurology 74(24), 2022–2024 (2010).
  • PRISMS (Prevention of Relapses and Disability by Interferon β-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet 352(9139), 1498–1504 (1998).
  • Polman CH, O’Connor PW, Havrdova E et al.; AFFIRM Investigators. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 354(9), 899–910 (2006).
  • Mikol DD, Barkhof F, Chang P et al.; REGARD study group. Comparison of subcutaneous interferon β-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol. 7(10), 903–914 (2008).
  • O’Connor P, Filippi M, Arnason B et al.; BEYOND Study Group. 250 microg or 500 microg interferon β-1b versus 20 mg glatiramer acetate in relapsing–remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol. 8(10), 889–897 (2009).
  • Río J, Tintoré M, Sastre-Garriga J et al. Change in the clinical activity of multiple sclerosis after treatment switch for suboptimal response. Eur. J. Neurol. 19(6), 899–904 (2012).
  • Prosperini L, Gallo V, Petsas N, Borriello G, Pozzilli C. One-year MRI scan predicts clinical response to interferon β in multiple sclerosis. Eur. J. Neurol. 16(11), 1202–1209 (2009).
  • Río J, Rovira A, Tintoré M et al. Relationship between MRI lesion activity and response to IFN-β in relapsing–remitting multiple sclerosis patients. Mult. Scler. 14(4), 479–484 (2008).
  • Havrdova E, Galetta S, Hutchinson M et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing–Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol. 8(3), 254–260 (2009).
  • Khatri BO, Barkhof F, Comi G, Jin J, Francis G, Cohen JA. Fingolimod treatment increases the proportion of patients who are free from disease activity in multiple sclerosis compared to interferon β-1a: results from a Phase 3 active-controlled study (TRANSFORMS). Presented at: 64th American Academy of Neurology Annual Meeting. New Orleans, LA, USA, 21–28 April 2012.
  • Miller DH, Soon D, Fernando KT et al.; AFFIRM Investigators. MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurology 68(17), 1390–1401 (2007).
  • Rudick RA, Fisher E, Lee JC, Simon J, Jacobs L. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing–remitting MS. Multiple Sclerosis Collaborative Research Group. Neurology 53(8), 1698–1704 (1999).
  • Rovaris M, Comi G, Rocca MA, Wolinsky JS, Filippi M; European/Canadian Glatiramer Acetate Study Group. Short-term brain volume change in relapsing–remitting multiple sclerosis: effect of glatiramer acetate and implications. Brain 124(Pt 9), 1803–1812 (2001).
  • Sormani MP, Rovaris M, Valsasina P, Wolinsky JS, Comi G, Filippi M. Measurement error of two different techniques for brain atrophy assessment in multiple sclerosis. Neurology 62(8), 1432–1434 (2004).
  • Rudick RA, Polman CH. Current approaches to the identification and management of breakthrough disease in patients with multiple sclerosis. Lancet Neurol. 8(6), 545–559 (2009).
  • Cohen M, Maillart E, Papeix C et al. ENIGM: a french observational study about switching from natalizumab to fingolimod in multiple sclerosis. Presented at: American Academy of Neurology 65th Annual Meeting San Diego, CA, USA, 16–23 March 2013.
  • The IFNB Multiple Sclerosis Study Group. Interferon β-1b is effective in relapsing–remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43(4), 655–661 (1993).
  • Comi G, Jeffery D, Kappos L et al.; ALLEGRO Study Group. Placebo-controlled trial of oral laquinimod for multiple sclerosis. N. Engl. J. Med. 366(11), 1000–1009 (2012).
  • Ontaneda D, Hara-Cleaver C, Rudick RA, Cohen JA, Bermel RA. Early tolerability and safety of fingolimod in clinical practice. J. Neurol. Sci. 323(1–2), 167–172 (2012).
  • Cohen JA, Coles AJ, Arnold DL et al.; CARE-MS I investigators. Alemtuzumab versus interferon β 1a as first-line treatment for patients with relapsing–remitting multiple sclerosis: a randomised controlled Phase 3 trial. Lancet 380(9856), 1819–1828 (2012).
  • Coles AJ, Twyman CL, Arnold DL et al.; CARE-MS II investigators. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled Phase 3 trial. Lancet 380(9856), 1829–1839 (2012).
  • Clatworthy MR, Wallin EF, Jayne DR. Anti-glomerular basement membrane disease after alemtuzumab. N. Engl. J. Med. 359(7), 768–769 (2008).
  • Coles AJ, Compston DA, Selmaj KW et al.; CAMMS223 Trial Investigators. Alemtuzumab vs. interferon β-1a in early multiple sclerosis. N. Engl. J. Med. 359(17), 1786–1801 (2008).
  • Giovannoni G, Gold R, Selmaj K et al. A randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of daclizumab HYP monotherapy in relapsing–remitting multiple sclerosis: primary results of the SELECT trial. Presented at: 5th Joint Triennial Congress of the European and Americas Committees for Treatment and Research in Multiple Sclerosis. Amsterdam, The Netherlands, 19–22 October 2011.
  • Wolinsky JS, Narayana PA, O’Connor P et al. Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann. Neurol. 61(1), 14–24 (2007).
  • Hawker K, O’Connor P, Freedman MS et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann. Neurol. 66(4), 460–471 (2009).
  • Kita M, Cohen J, Fox R et al. A Phase II trial of mitoxantrone in patients with primary progressive multiple sclerosis. Neurology 62, A99 (2004) (Abstract).
  • Graeler M, Goetzl EJ. Activation-regulated expression and chemotactic function of sphingosine 1-phosphate receptors in mouse splenic T cells. FASEB J. 16(14), 1874–1878 (2002).
  • Cinamon G, Matloubian M, Lesneski MJ et al. Sphingosine 1-phosphate receptor 1 promotes B cell localization in the splenic marginal zone. Nat. Immunol. 5(7), 713–720 (2004).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.